Journal Publication

Tiragolumab-atezolizumab combo raises rash and infusion-reaction risk, meta-analysis finds

A pooled analysis of five randomized trials in 1,001 patients links dual TIGIT/PD-L1 blockade to more skin and infusion toxicity without a rise in severe adverse events.

By AppliedXLJuly 14, 2026

Executive Summary

Adding TIGIT blockade to PD-L1 blockade raises specific, manageable skin and infusion toxicities without increasing severe adverse events.
A pooled analysis of randomized trials isolates which adverse events are attributable to the added TIGIT-targeting antibody rather than to the PD-L1 backbone alone.
The toxicity pattern gives clinicians a defined signal to monitor for dermatologic and infusion-related events when the combination is used, while severe-toxicity rates remain unchanged from PD-L1 blockade alone.
The authors themselves note that the number of pooled trials is limited and the studies are clinically heterogeneous, calling for caution in generalizing the result and for continued long-term safety follow-up.

The stake

Dual blockade of TIGIT (T-cell immunoreceptor with Ig and ITIM domains) and PD-L1 (programmed death-ligand 1) is designed to produce synergistic antitumor activity by combining two distinct immune-checkpoint mechanisms, but combining checkpoint inhibitors can also compound toxicity. The review's authors state that the safety profile of tiragolumab plus atezolizumab (TA) "remains incompletely defined," and set out to quantify it against atezolizumab-based regimens alone. Safety

How it was done

The authors conducted a systematic literature search through March 2026, restricting eligible studies to Phase II or III randomized controlled trials that compared the TA combination against atezolizumab-based regimens and reported adverse events. Five trials covering 1,001 patients met the criteria, and the team pooled risk ratios (RRs) with 95% confidence intervals across organ-system and severity-graded adverse-event categories, including a subgroup analysis isolating TA against atezolizumab alone. Safety

The results

TA carried a higher risk of rash (RR 1.66, 95% CI 1.16 to 2.37), pruritus (RR 2.28, 95% CI 1.65 to 3.16), and infusion-related reactions (RR 1.80, 95% CI 1.23 to 2.62) than the comparator regimens. Gastrointestinal, hematologic, endocrine, laboratory, and high-grade adverse events showed no statistically significant difference between arms. In the subgroup limited to TA versus atezolizumab alone, only rash reached statistical significance, at a larger effect size (RR 3.85, 95% CI 1.40 to 10.53). Safety

What it means for the regimen

The pattern that emerges is toxicity concentrated in skin and infusion reactions rather than in the organ-system or high-grade categories that typically drive treatment discontinuation. That distinction matters because it separates the added burden of TIGIT blockade from the more consequential severe-toxicity profile, which the pooled data show is unchanged from PD-L1 blockade alone. Safety

The caveat

The authors describe their own evidence base as limited by trial number and clinical heterogeneity across the five studies, and call for further long-term safety evaluation of the combination. Safety

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.